Growth Hormone's Effect on the Cardiovascular System

• Register: ClinicalTrials.gov
• Last refreshed on: 17 October 2012
• Main ID: NCT00397319
• Date of registration: 08/11/2006
• Primary sponsor: Vanderbilt University
• Public title: Growth Hormone's Effect on the Cardiovascular System
• Scientific title: The Role of Growth Hormone in Cardiovascular Health
• Date of first enrolment: August 2005
• Target sample size: 26
• Recruitment status: Terminated
• URL: http://clinicaltrials.gov/show/NCT00397319
• Study type: Observational
• Study design: Observational Model: Case Control, Time Perspective: Longitudinal, Time Perspective: Prospective

Countries of recruitment

United States

Contacts

• Name: Doug Vaughan, MD
• Affiliation: Vanderbilt University

Key inclusion & exclusion criteria

Inclusion Criteria:

- Adult between the ages of 18 and 65

- Documented Growth Hormone Deficiency as defined by a peak Growth Hormone during a
GHRH-Arginine Stimulation test not exceeding 9.5 ng/ml

Exclusion Criteria:

- Personal history of cardiovascular disease (previous myocardial infarction or known
coronary artery disease) or diagnosis of heart disease between study visits.

- Personal history of diabetes mellitus or development of diabetes between study
visits.

- Initiation of an anti-cholesterol medication or anti-hypertensive between baseline
and follow-up study visit.

- Initiation of regular tobacco use between baseline and follow-up study visit.

- Pregnancy or nursing

- Current daily use of any drug known to affect the fibrinolytic system: Aspirin,
Aggrenox, Plavix, Persantine, Ticlid, Pletal, Trental, Lovenox, Coumadin, Agrylin,
and Hydroxyurea.



Age minimum: 18 Years
Age maximum: 65 Years
Gender: Both

Health Condition(s) or Problem(s) studied

Growth Hormone Deficiency

Intervention(s)

Drug: Growth Hormone

Secondary ID(s)

050045

1422

Source(s) of Monetary Support

Please refer to primary and secondary sponsors

Secondary Sponsor(s)

National Center for Research Resources (NCRR)

Pfizer